Statistics

Total Visits

Views
Weekly cabazitaxel in "unfit" metastatic castration-resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment: Preliminary results of CABASEM-SOGUG phase II trial.19

Select a period of time:

Number of views in the range

Views
Weekly cabazitaxel in "unfit" metastatic castration-resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment: Preliminary results of CABASEM-SOGUG phase II trial.8

Views

Views
May 20244
June 20241
July 20241
August 20241
September 20240
October 20241
November 20240
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States6
Belgium1
 

Top cities views

Views
Chicago3